Back to top
more

Baxter International (BAX)

(Delayed Data from NYSE)

$35.87 USD

35.87
3,167,156

+0.17 (0.48%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $35.75 -0.12 (-0.33%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (74 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

Edwards Lifesciences Hits a 52-Week High on Solid Prospects

Edwards Lifesciences (EW) gains from recent impressive developments.

LivaNova's (LIVN) Study to Evaluate VNS Therapy Gets CMS Nod

LivaNova (LIVN) is aiming to reach out to more patients, with improved enrollment program.

Here's Why You Should Invest in Amedisys (AMED) Right Now

Amedisys (AMED) is currently enjoying investors' confidence, thanks to solid prospects.

Here's Why You Should Invest in Integer Holdings (ITGR) Now

Integer Holdings (ITGR) continues to benefit from portfolio management, strong foothold in the broader MedTech space and rising Non-Medical sales.

What's in Store for Aurora Cannabis (ACB) in Q4 Earnings?

Aurora Cannabis (ACB) expects revenues within $100-$107 million in fiscal Q4.

Here's Why You Should Invest in Chemed (CHE) Stock Right Now

Investors continue to be optimistic about Chemed's (CHE) performance.

Masimo (MASI) Introduces Pathway, Boosts Patient Monitoring

Masimo's (MASI) new feature, Pathway, is likely to help clinicians simplify their workflow associated with newborn resuscitation, thereby improving patient monitoring.

Stryker's Mobius Imaging Buyout to Boost Its Spine Division

Stryker (SYK) expects the buyout to remain neutral to its 2019 earnings.

Here's Why You Should Invest in Edwards Lifesciences (EW) Now

Investors continue to be optimistic about Edwards Lifesciences' (EW) performance.

Here's Why You Should Hold on to Hill-Rom (HRC) Stock Now

Investors' optimism continues to be high on solid prospects of Hill-Rom Holdings (HRC).

HealthEquity (HQY) Earnings & Revenues Beat Estimates in Q2

HealthEquity (HQY) gains from solid segmental contributions in second-quarter fiscal 2020.

Integra LifeSciences' Organic Growth Strong on New Products

Gaining traction from product unveilings and an improved sales force performance, Integra LifeSciences (IART) expects rapid organic growth in the second half of 2019.

Medtronic Names Next CEO as Omar Ishrak to Step Down in 2020

This is indeed a top story as during Omar's tenure, annual revenues of Medtronic (MDT) skyrocket to double-digit growth among a slew of enormous feats that he attains.

Bruker (BRKR) Releases JPK NanoWizard 4 XP Bio-AFM System

With the launch of this new system, Bruker (BRKR) establishes a performance yardstick for atomic force microscopy in the field of life science research.

Here's Why You Should Invest in Haemonetics (HAE) Right Now

Haemonetics (HAE) has been enjoying investors' rising optimism, owing to solid prospects.

Here's Why You Should Hold on to DexCom (DXCM) Stock Now

DexCom (DXCM) continues to benefit from growing glucose monitoring market, strategic buyouts and strong international presence. However, margin contraction remains a woe.

Here's Why You Should Hold on to Thermo Fisher (TMO) for Now

Investors continue to be optimistic about Thermo Fisher's (TMO) performance.

Here's Why You Should Consider Betting on CONMED Stock Now

CONMED (CNMD) continues to benefit from robust international sales, broad product portfolio and persistent focus on R&D.

Here's Why You Should Retain PerkinElmer (PKI) Stock Now

PerkinElmer (PKI) is gaining steadily from core Diagnostics segment, prudent acquisitions and margin expansion. However, forex volatility remains a concern.

HealthEquity Acquires WageWorks, To Make Notable Investments

HealthEquity (HQY) expects to complete its $80-100 million investment program within 24-36 months from now.

Here's Why You Should Invest in Hologic (HOLX) Stock Now

Hologic (HOLX) is generating consistently positive results, thanks to impressive developments.

Zimmer Biomet Succeeds in Priority Areas, Suffers Pricing Woe

With regard to product suite, Zimmer Biomet (ZBH) steadily wins an array of key regulatory clearances for knee, brain and spine applications under its ROSA platform over the past several months.

What's in the Cards for HealthEquity (HQY) in Q2 Earnings?

Higher revenues and possible margin expansion are likely to aid HealthEquity (HQY) in Q2 earnings.

Cooper Companies (COO) Q3 Earnings Beat, Revenues Rise Y/Y

Cooper Companies (COO) gains from solid segmental contributions in fiscal Q3.

Quest Diagnostics' New Acquisitions and Pacts Aid Growth

Quest Diagnostics' (DGX) nine deals concluded in 2018 strengthen its potential to fulfill its goals set for 2019.